ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program
ZoeNCure Therapeutics has raised INR 20 crore in seed funding to advance its antibody drug conjugate (ADC) program for treating liver and gastrointestinal cancers. The investment will support preclinical studies and regulatory filings in India.
Why it matters
This highlights the growth of the biotech startup ecosystem in India and the increasing focus on targeted oncology therapies.
Gurugram, Haryana, New Delhi, Delhi, India – Business Wire India
ZoeNCure Therapeutics Pvt. Ltd . , an oncology biotechnology company focused on developing high-potency targeted cancer therapies, today announced the successful closing of an INR 20 Crore (approx. $2.4 Million USD) Seed financing round. The investment was led by the HNI (High-Net-Worth Individual) Tyagi Family based out of Gurugram, India, led by Mr. Shyambir Tyagi and Manoj Tyagi, alongside participating angel co-investors.
This round represents the second financial backing from the said Tyagi Family, which previously provided an INR 2.5 Crore pre-seed investment to fund ZoeNCure ‘s foundational operations. The follow-on capital brings the total equity raised by the company to INR 22.5 Crore, reflecting strong investor confidence and conviction in ZoeNCure’s pipeline progress, strategic licensing strategy, and execution capabilities.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in